Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell Sells 7,500 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Amicus Therapeutics Stock Down 4.3 %

Shares of NASDAQ FOLD opened at $11.24 on Thursday. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The firm’s 50 day moving average price is $11.15 and its 200 day moving average price is $10.61. The firm has a market cap of $3.33 billion, a P/E ratio of -28.82 and a beta of 0.68. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. Amicus Therapeutics’s revenue was up 34.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.15) earnings per share. As a group, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Hedge Funds Weigh In On Amicus Therapeutics

A number of large investors have recently bought and sold shares of FOLD. Duality Advisers LP raised its stake in Amicus Therapeutics by 40.3% during the first quarter. Duality Advisers LP now owns 37,555 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 10,792 shares during the period. SG Americas Securities LLC purchased a new position in Amicus Therapeutics during the first quarter worth approximately $291,000. Mesirow Institutional Investment Management Inc. purchased a new position in Amicus Therapeutics during the first quarter worth approximately $372,000. Swiss National Bank raised its stake in Amicus Therapeutics by 2.3% during the first quarter. Swiss National Bank now owns 434,300 shares of the biopharmaceutical company’s stock worth $5,116,000 after purchasing an additional 9,900 shares during the period. Finally, Sei Investments Co. raised its stake in Amicus Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 222,715 shares of the biopharmaceutical company’s stock worth $2,624,000 after purchasing an additional 19,366 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently commented on FOLD. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. Morgan Stanley lowered their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. JPMorgan Chase & Co. lowered their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.13.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.